Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.

Authors: Im, SH  Barchan, D  Fuchs, S  Souroujon, MC 
Citation: Im SH, etal., J Clin Invest 1999 Dec;104(12):1723-30.
Pubmed: (View Article at PubMed) PMID:10606626
DOI: Full-text: DOI:10.1172/JCI8121

Myasthenia gravis (MG) is an autoimmune disorder in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. In an attempt to develop an antigen-specific therapy for MG, we administered a nonmyasthenogenic recombinant fragment of AChR orally to rats. This fragment, corresponding to the extracellular domain of the human AChR alpha-subunit (Halpha1-205), protected rats from subsequently induced experimental autoimmune myasthenia gravis (EAMG) and suppressed ongoing EAMG when treatment was initiated during either the acute or chronic phases of disease. Prevention and suppression of EAMG were accompanied by a significant decrease in AChR-specific humoral and cellular responses. The underlying mechanism for the Halpha1-205-induced oral tolerance seems to be active suppression, mediated by a shift from a T-helper 1 (Th1) to a Th2/Th3 response. This shift was assessed by changes in the cytokine profile, a deviation of anti-AChR IgG isotypes from IgG2 to IgG1, and a suppressed AChR-specific delayed-type hypersensitivity response. Our results in experimental myasthenia suggest that oral administration of AChR-specific recombinant fragments may be considered for antigen-specific immunotherapy of myasthenia gravis.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 704386
Created: 2003-09-18
Species: All species
Last Modified: 2003-09-18
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.